Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.43 |
| ▸ | TYR | P14679 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31395450 | 1.00 | HTT (0.48) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL17374025 | 0.89 | ALDH1A1 (0.50) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL28299697 | 0.85 | CYP19A1 (0.54) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL30640325 | 0.83 | CYP19A1 (0.53) | HTTNPC1HPGDMAPK1RAB9A | |
| Formaldehyde SCHEMBL27643836 | 0.82 | ALOX5 (0.44) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL11036424 | 0.81 | ALDH1A1 (0.47) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL69778 | 0.80 | MAPT (0.53) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL18371595 | 0.80 | CYP19A1 (0.53) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL574465 | 0.80 | ALDH1A1 (0.53) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL22692794 | 0.79 | CYP19A1 (0.49) | HTTNPC1HPGDMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528776-B1 | REDUCED-ETHANOL MOUTH RINSE FORMULATIONS | KENVUE BRANDS LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12201987-B2 | Pipette tip rack | BIOTIX, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-11857653-B2 | Method of providing an oral care benefit using a poorly-soluble calcium compound and fluoride | JOHNSON & JOHNSON CONSUMER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11648186-B2 | Coated particles and their uses | JOHNSON & JOHNSON CONSUMER INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11590490-B2 | Pipette tips | BIOTIX, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220331222-A1 | Method of Providing Oral Care Benefits | KENVUE BRANDS LLC | 2022-10-20 | — | — | US | disclosed |
| US-20220226205-A1 | Coated Particles and Their Uses | KENVUE BRANDS LLC | 2022-07-21 | — | — | US | disclosed |
| US-11351103-B2 | Method of providing oral care benefits | JOHNSON & JOHNSON CONSUMER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11291613-B2 | Coated particles and their uses | JOHNSON & JOHNSON CONSUMER INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3897511-A1 | METHOD OF PROVIDING AN ORAL CARE BENEFIT USING A POORLY-SOLUBLE CALCIUM COMPOUND AND FLUORIDE | Johnson & Johnson Consumer Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-5776435-A | DENTIFRICES | COLGATE-PALMOLIVE COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| US-5686064-A | MIXTURE INCLUDES TETRAALKALI METAL POLYPHOSPHATE AND TRICLOSAN; DENTIFRICES | COLGATE PALMOLIVE COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5681548-A | CONTAINING AMPHOTERIC SURFACTANT AND MICROBIOCIDE | COLGATE PALMOLIVE COMPANY (US) | 1997-10-28 | — | — | US | disclosed |
| US-5575652-A | Process for applying antibacterial oral composition to dental implant areas | COLGATE PALMOLIVE COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| US-5538715-A | DENTIFRICES WITH ANTIPLAQUE AGENTS FOR MOUTHS WITH HUMECTANTS, SILICA POLISHES AND BACTERICIDES | COLGATE PALMOLIVE COMPANY (US) | 1996-07-23 | — | — | US | disclosed |
| US-5288480-A | Antiplaque antibacterial oral composition | COLGATE-PALMOLIVE CO. (US) | 1994-02-22 | — | — | US | disclosed |
| US-5192530-A | Solubilizer, enhancing agent to aid retention, and delivery enhancement | COLGATE-PALMOLIVE COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
| US-5178851-A | Dentifrices treatment with triclosan and carriers | COLGATE-PALMOLIVE COMPANY (US) | 1993-01-12 | — | — | US | disclosed |
| US-5080887-A | Polyphosphate, bactericide | COLGATE-PALMOLIVE COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-4894220-A | WATER AND ALCOHOL SOLVENTS, GLYCOL DERIVATIVES AND ESTERS SOLUTIONS | COLGATE-PALMOLIVE COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291613-B2 | Coated particles and their uses | CD63, EPCAM, CD44 | HTT 1520/4885NPC1 2820/4885HPGD 3992/4885 |
| US-11648186-B2 | Coated particles and their uses | CD63, EPCAM, CD44 | HTT 1520/4885NPC1 2820/4885HPGD 3992/4885 |
| US-20220226205-A1 | Coated Particles and Their Uses | CD63, EPCAM, CD44 | HTT 1520/4885NPC1 2820/4885HPGD 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.